PMID- 35829988
OWN - NLM
STAT- MEDLINE
DCOM- 20221111
LR  - 20221111
IS  - 1720-8386 (Electronic)
IS  - 0391-4097 (Linking)
VI  - 45
IP  - 12
DP  - 2022 Dec
TI  - Chinese patients with type 2 diabetes mellitus and nonalcoholic fatty liver 
      disease have lower serum osteocalcin levels compared to individuals with type 2 
      diabetes mellitus and no liver disease: a single-center cross-sectional study.
PG  - 2275-2282
LID - 10.1007/s40618-022-01861-z [doi]
AB  - PURPOSE: Osteocalcin may benefit nonalcoholic fatty liver disease (NAFLD). The 
      present study aimed to explore the levels of serum osteocalcin in NAFLD in 
      patients with type 2 diabetes mellitus (T2DM). METHODS: In total, 1026 inpatients 
      diagnosed with T2DM were enrolled in the study. NAFLD was defined according to 
      the working definition of the revised guidelines for the management of NAFLD 
      published by the Chinese Liver Disease Association, and confirmed by abdominal 
      ultrasonography. RESULTS: The current study found a NAFLD prevalence of 54% in 
      the T2DM population. Subjects with NAFLD had lower concentrations of osteocalcin 
      (8.28-13.99 ng/mL vs. 8.80-16.25 ng/mL, P = 0.001) but similar vitamin D, 
      parathyroid hormone, beta-C-terminal telopeptide of type I collagen and 
      procollagen type 1 N-peptide levels. Osteocalcin levels (OR: 0.956; 95% CI 
      0.926-0.987) were significantly associated with NAFLD. When all significant 
      clinical indicators were analyzed together, increased BMI (OR: 1.120; 95% CI 
      1.065-1.178), fasting C-peptide (OR: 1.270; 95% CI 1.089-1.481) and triglycerides 
      (OR: 1.661; 95% CI 1.284-2.148) were associated with a greater risk of NAFLD, 
      while older age (OR: 0.967; 95% CI 0.948-0.986) and high osteocalcin levels (OR: 
      0.935; 95% CI 0.902-0.969) were related with a decreased risk of NAFLD. For every 
      additional unit of osteocalcin, the patients received 7% deduced odds of NAFLD. 
      CONCLUSION: Low osteocalcin levels were associated with an increased risk for 
      NAFLD in patients with T2DM.
CI  - (c) 2022. The Author(s), under exclusive licence to Italian Society of 
      Endocrinology (SIE).
FAU - Fu, J
AU  - Fu J
AUID- ORCID: 0000-0003-0129-519X
AD  - Department of Endocrinology, Beijing Institute of Geriatrics, Xuanwu Hospital, 
      Capital Medical University, Beijing, 100053, China.
FAU - Mu, Z
AU  - Mu Z
AD  - Department of Endocrinology, Beijing Institute of Geriatrics, Xuanwu Hospital, 
      Capital Medical University, Beijing, 100053, China.
FAU - Sun, L
AU  - Sun L
AD  - Department of Endocrinology, Beijing Institute of Geriatrics, Xuanwu Hospital, 
      Capital Medical University, Beijing, 100053, China.
FAU - Gao, X
AU  - Gao X
AD  - Department of Endocrinology, Beijing Institute of Geriatrics, Xuanwu Hospital, 
      Capital Medical University, Beijing, 100053, China.
FAU - Hu, X
AU  - Hu X
AD  - Department of Endocrinology, Beijing Institute of Geriatrics, Xuanwu Hospital, 
      Capital Medical University, Beijing, 100053, China.
FAU - Xiu, S
AU  - Xiu S
AD  - Department of Endocrinology, Beijing Institute of Geriatrics, Xuanwu Hospital, 
      Capital Medical University, Beijing, 100053, China. xiushuangling@126.com.
LA  - eng
GR  - PX2020034/Beijing Municipal Administration of Hospitals Incubating Program/
GR  - QNPY2020014/Xuanwu Hospital Science Program for Fostering Young Scholars/
GR  - PYZ21033/Capital Medical University Scientific Research Cultivation Fund/
GR  - 11000022T000000461062/The Pilot Project for Public Welfare Development and Reform 
      of Beijing-affiliated Medical Research Institutes-Research on Intelligent 
      Management and Innovative Model of Chronic Diseases in Elderly/
PT  - Journal Article
DEP - 20220713
PL  - Italy
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
RN  - 104982-03-8 (Osteocalcin)
SB  - IM
MH  - Humans
MH  - *Non-alcoholic Fatty Liver Disease
MH  - Osteocalcin
MH  - *Diabetes Mellitus, Type 2
MH  - Cross-Sectional Studies
MH  - China/epidemiology
OTO - NOTNLM
OT  - Bone turnover markers
OT  - Nonalcoholic fatty liver disease
OT  - Osteocalcin
OT  - Type 2 diabetes mellitus
EDAT- 2022/07/14 06:00
MHDA- 2022/11/15 06:00
CRDT- 2022/07/13 11:24
PHST- 2022/04/05 00:00 [received]
PHST- 2022/07/03 00:00 [accepted]
PHST- 2022/07/14 06:00 [pubmed]
PHST- 2022/11/15 06:00 [medline]
PHST- 2022/07/13 11:24 [entrez]
AID - 10.1007/s40618-022-01861-z [pii]
AID - 10.1007/s40618-022-01861-z [doi]
PST - ppublish
SO  - J Endocrinol Invest. 2022 Dec;45(12):2275-2282. doi: 10.1007/s40618-022-01861-z. 
      Epub 2022 Jul 13.